Milestone Pharmaceuticals enrolls first European patient in AFib trial

October 9, 2026 8:00 AM

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) announced that the first European participant has been enrolled in its ReVeRA-301 Phase 3 clinical ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found